From these observations, VEGFR-1/PlGF targeting could be of clinical benefit in neoplasms such as PC, which have shown a poor response to VEGFR-2 targeting approaches and are associated with aberrant VEGFR-1/PlGF signaling. The gene discussed is PGF; the disease is pachyonychia congenita.